American Bio Medica Receives Patent for the Rapid One Product Line.

Business Editors

KINDERHOOK, N.Y.--(BUSINESS WIRE)--Feb. 7, 2000

American Bio Medica Corp. (NASDAQ: ABMC) today reported that the U.S. Patent and Trademark Office have issued a patent for the Company's Rapid One(TM) single dipstick product line.

The patent covers the design of the Rapid One single dipstick. The Rapid One product line was released in July of 1998 and individually screens for the presence or absence of 10 substances of abuse. This offers customers flexibility in regards to their testing needs. The product line is especially useful in the corrections market and any other circumstance where the person subject to testing is suspected to be abusing a specific drug.

&uot;The Rapid One again demonstrates our ability to meet market demands as they arise,&uot; stated Douglas Casterlin, ABMC Vice President of Operations and inventor of the Rapid One. &uot;We are pleased to have yet another addition to our expanding portfolio of patents and trademarks worldwide. The Company will continue to secure our position in the market by protecting our intellectual property rights.&uot;

The Company's Rapid Drug Screen(TM) family of products generates results in five minutes and is unrivaled in the market for ease of use. The most secure and flexible total testing system on the market, ABMC's Rapid Drug Screen simultaneously screens for the presence or absence of up to nine illicit drugs. The Company's Drug Detector(TM) is a non-invasive on-site drug detection system; which tests for the presence or absence of substances of abuse without the need for hair, saliva, or urine samples.

American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate, on-site drugs of abuse diagnostic kits, sprays and support services worldwide. The Company's global distributors target the workplace, clinical, physicians, corrections and educational markets. ABMC's Drug Detector identifies minute traces of illegal drugs on surfaces, while the Company's Rapid Drug Screen tests individuals and is proven to correlate 100% with the standard laboratory screening test.

Forward-looking statements in this release are made pursuant to the &uot;safe harbor&uot; provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.